It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
Dezeen Showroom: Italian brand Fiandre aimed to create a "vocabulary of surfaces" with the Lexicon tile collection, featuring eight high-tech stone- and marble-inspired designs. Both atmospheric, ...
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...
Destinations International (DI), the world’s leading association for destination organizations, will proudly mark World Tourism Lexicon Day tomorrow, November 13, with release of the 2025 Tourism ...
Some Dún Laoghaire doors were slammed in canvassing politicians’ faces in advance of the 2014 local elections if they admitted they supported the then yet to open library, according to local ...
Abstract: This hands-on tutorial teaches participants how to audit static analysis alerts, using an auditing lexicon and rules. There is no widely-accepted lexicon or standard set of rules for ...
THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback